All data are based on the daily closing price as of August 7, 2025
e

Eisai

4523.TSE
29.48 USD
0.72
+2.50%

Overview

Last close
29.48 usd
Market cap
8.32B usd
52 week high
44.70 usd
52 week low
24.09 usd
Target price
30.72 usd

Valuation

P/E
26.0774
Forward P/E
32.6797
Price/Sales
1.5234
Price/Book Value
1.4468
Enterprise Value
7.82B usd
EV/Revenue
1.4588
EV/EBITDA
11.0206

Key financials

Revenue TTM
5.45B usd
Gross Profit TTM
4.29B usd
EBITDA TTM
687.22M usd
Earnings per Share
1.11 usd
Dividend
1.09 usd
Total assets
9.30B usd
Net debt
-523.43M usd

About

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neuropathy; Jyseleca, a janus kinase inhibitor; Goofice for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, treatment for dementia; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
  • Symbol
    4523.TSE
  • Exchange
    TSE
  • Isin
    JP3160400002
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Haruo Naito
  • Headquarter
    Tokyo
  • Web site
    https://www.eisai.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top